Skip to main content
CDT
NASDAQ Life Sciences

CDT Equity Seeks Shareholder Approval for Catastrophic Dilution: 12.1M Pre-Funded Warrant Shares and Amended Toxic Note Terms

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$3.299
Mkt Cap
$2.447M
52W Low
$2.53
52W High
$3,800
52W Position info
30% above low
Off High info
100% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

CDT sits 30% above its 52-week low of $2.53 on light trading volume (0.1× avg).

Summary

CDT Equity's definitive proxy seeks approval for up to 12.1 million shares from pre-funded warrants and reveals amended, more toxic terms on a $2.5M convertible note — extreme dilution for a company with only 786K shares outstanding and a going-concern warning.


Key Events · Corporate Governance and Compliance · CDT

  • 12.1M Pre-Funded Warrant Shares Up for Vote

    Proposal 5 asks shareholders to approve the issuance of up to 12,131,770 shares upon exercise of pre-funded warrants issued to Sarborg stockholders — over 15 times the current 786,716 shares outstanding, representing potential dilution exceeding 1,500%.

  • Amended J.J. Astor Note Terms Worsen

    Proposal 4 reveals the convertible note principal has increased to $2,536,650, an additional 37,500 warrants were issued, and the conversion price is now 70% of the lowest VWAP over 20 days with a floor that resets to 20% of the lowest VWAP every six months — classic toxic financing features.

  • Cash Crisis and Going Concern Backdrop

    The company had only $97,000 in cash as of its last 10-Q and a going-concern warning. These proposals are essential to fund operations but will massively dilute existing shareholders.

  • Meeting Set for August 28, 2026

    The virtual annual meeting is scheduled for August 28, 2026, with a record date of August 3, 2026. Shareholders will vote on all proposals, including the reverse split authorization and the dilutive issuances.


Analysis · CDT · Life Sciences

CDT Equity's definitive proxy asks shareholders to approve the issuance of up to 12.1 million shares upon exercise of pre-funded warrants — a number that dwarfs the current 786,716 shares outstanding, representing potential dilution of over 1,500%. The filing also reveals that the J.J. Astor convertible note has been amended to include even more punitive terms: the total principal balance has grown to $2.5 million, an additional 37,500 warrants were issued, and the conversion price formula now uses 70% of the lowest VWAP over 20 days with a floor that resets downward every six months. These are classic death-spiral features that could decimate existing shareholders. The company is already in a cash crisis with a going-concern warning, and this proxy is a desperate plea to enable the massive share issuance needed to keep the lights on — but at a catastrophic cost to current investors.

At the time of this filing, CDT was trading at $3.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4M. The 52-week trading range was $2.53 to $3,800.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CDT - Latest Insights

CDT
Jul 31, 2026, 5:29 PM EDT
Filing Type: PRE 14A
Importance Score:
9
Price at Filing: $2.92
Real-time Price: $3.30 info
Change: +$0.3842 (+13%) info
Market Cap: $2.447M info
CDT
Jul 31, 2026, 5:26 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.87
Real-time Price: $3.30 info
Change: +$0.4292 (+15%) info
Market Cap: $2.447M info
CDT
Jul 16, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.322
Real-time Price: $3.30 info
Change: Reverse Stock Split info
Market Cap: $2.447M info
CDT
Jul 16, 2026, 8:04 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $0.2815
Real-time Price: $3.30 info
Change: Reverse Stock Split info
Market Cap: $2.447M info
CDT
Jul 15, 2026, 4:51 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.3503
Real-time Price: $3.30 info
Change: Reverse Stock Split info
Market Cap: $2.447M info